[go: up one dir, main page]

AU2001269077A1 - Methods and means for regulation of gene expression - Google Patents

Methods and means for regulation of gene expression

Info

Publication number
AU2001269077A1
AU2001269077A1 AU2001269077A AU6907701A AU2001269077A1 AU 2001269077 A1 AU2001269077 A1 AU 2001269077A1 AU 2001269077 A AU2001269077 A AU 2001269077A AU 6907701 A AU6907701 A AU 6907701A AU 2001269077 A1 AU2001269077 A1 AU 2001269077A1
Authority
AU
Australia
Prior art keywords
regulation
methods
gene expression
gene
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269077A
Inventor
Gennaro Ciliberto
Riccardo Cortese
Carlo Toniatti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Publication of AU2001269077A1 publication Critical patent/AU2001269077A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001269077A 2000-06-20 2001-06-15 Methods and means for regulation of gene expression Abandoned AU2001269077A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0015119 2000-06-20
GBGB0015119.1A GB0015119D0 (en) 2000-06-20 2000-06-20 Methods and means for regulation of gene expression
PCT/EP2001/006792 WO2001098506A2 (en) 2000-06-20 2001-06-15 Methods and means for regulation of gene expression

Publications (1)

Publication Number Publication Date
AU2001269077A1 true AU2001269077A1 (en) 2002-01-02

Family

ID=9894063

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269077A Abandoned AU2001269077A1 (en) 2000-06-20 2001-06-15 Methods and means for regulation of gene expression

Country Status (7)

Country Link
US (1) US20030109678A1 (en)
EP (1) EP1297161A2 (en)
JP (1) JP2004500884A (en)
AU (1) AU2001269077A1 (en)
CA (1) CA2413468A1 (en)
GB (1) GB0015119D0 (en)
WO (1) WO2001098506A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723102B2 (en) 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system
EP2968547B1 (en) 2013-03-15 2019-08-07 Memorial Sloan Kettering Cancer Center Multimerization technologies
MX2016013149A (en) * 2014-04-10 2017-04-27 Seattle Children's Hospital (Dba Seattle Children's Res Institute) Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection.
CN108174604B (en) 2015-08-07 2023-06-23 西雅图儿童医院（Dba西雅图儿童研究所） Bispecific CAR T cells for solid tumor targeting
MX2019006631A (en) * 2016-12-12 2019-11-12 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells.
US11325957B2 (en) 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
KR102109820B1 (en) * 2018-04-16 2020-05-12 한양대학교 산학협력단 Mutant estrogen receptor protein having improved binding capacity for Bisphenol A and bacterial strain using the same
CN114106123B (en) * 2021-11-22 2023-03-14 四川农业大学 Transcriptional activation domain TaL and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020951A1 (en) * 1994-12-29 1996-07-11 Massachusetts Institute Of Technology Chimeric dna-binding proteins
AU2053197A (en) * 1996-02-23 1997-09-10 Ariad Pharmaceuticals, Inc. Cell-based assay

Also Published As

Publication number Publication date
GB0015119D0 (en) 2000-08-09
EP1297161A2 (en) 2003-04-02
WO2001098506A2 (en) 2001-12-27
CA2413468A1 (en) 2001-12-27
WO2001098506A3 (en) 2002-04-25
US20030109678A1 (en) 2003-06-12
JP2004500884A (en) 2004-01-15

Similar Documents

Publication Publication Date Title
AU2002253836A1 (en) Aptamer-mediated regulation of gene expression
AU2001234608A1 (en) Methods for analysis of gene expression
AU2001253255A1 (en) Compositions and methods for inhibiting gene expression
AU4563300A (en) Regulation of viral gene expression
EP1177277A4 (en) Compositions and methods for the modification of gene transcription
AU2002212963A1 (en) Method of and structure for controlling electrode temperature
AU2001245987A1 (en) Compositions and methods for gene therapy
AU4206200A (en) Compounds and methods for stimulating beta-catenin mediated gene expression and differentiation
AU1723001A (en) Methods and means for regulation of gene expression
AU5328600A (en) Nucleotide sequences for gene regulation and methods of use thereof
EP1581614A3 (en) Nucleotide sequences for gene regulation and methods of use thereof
AU2001251138A1 (en) Compositions and methods for tissue specific gene regulation therapy
AU2001269077A1 (en) Methods and means for regulation of gene expression
AU2002222618A1 (en) Method of analyzing gene expression
AU6469699A (en) Method of regulating gene expression
WO2002077885A8 (en) Distribution system and method of operation thereof
AU2001236718A1 (en) Bioreactor and related method
AU2001278598A1 (en) Methods and means for gene silencing
AU2841500A (en) Dehiscence gene and methods for regulating dehiscence
AU2002359403A1 (en) METHODS AND COMPOSITIONS FOR REGULATION OF GENE EXPRESSION THROUGH MODULATION OF mRNA TURNOVER
AU2002219992A1 (en) Targeted regulation of gene expression
EP1163340A4 (en) Compositions and methods for the modification of gene expression
AU2002355155A1 (en) Methods for gene disruption and uses thereof
AU2001261343A1 (en) Method of regulating angiogenesis using ryk protein
AU7099400A (en) Methods and reagents for regulating gene expression